Helin-Tanninen M, Naaranlahti T, Kontra K, Wallenius K
Pharmacy Department, Kuopio University Hospital, Kuopio, FinlandFaculty of Social Pharmacy, University of Kuopio, Kuopio, Finland.
J Clin Pharm Ther. 2001 Feb;26(1):49-57. doi: 10.1046/j.1365-2710.2001.00318.x.
To formulate an oral suspension of nifedipine for paediatric use and to assess its content uniformity as well as the microbiological and physical stabilities of the hypromellose solution that was used in the formulation.
Six concentrations (0.5-3.0%) of hypromellose colloids and water as a blank were compounded with nifedipine, both as a powder and as crushed tablets, to a concentration of 1 mg/mL. Four different screening tests were used to find the most homogenous and dose-accurate combination. First, nifedipine suspensions were stored in vials for one month and visual homogenity of the redispersed suspensions was observed. Second, the homogenity of the suspensions was studied by measuring the nifedipine concentration from upper, middle and lower parts of the redispersed suspension. Next, the nifedipine concentration was measured from the suspensions immediately, 1 min and 2 min after shaking to ensure dose accuracy during the administration period. Finally, suspensions were packaged into oral disposable syringes and nifedipine concentrations were determined after one month of storage. Content uniformity of the packaged single-dose syringe suspensions was studied according to a method established by the European Pharmacopoeia. Microbiological stability, density, pH, osmolality, viscosity and surface tension of the hypromellose solution were studied over a 12-month storage period.
From the results of the screening tests of hypromellose solution, 1.0% hypromellose was chosen as the vehicle for nifedipine enteral suspensions, made from both crushed tablets and nifedipine powder. Nifedipine suspensions made from hypromellose 1.0% were easiest to redisperse as a homogenous solution, and it also appeared best on visual inspection. The content uniformity of the suspension complied with the test recommended by the European Pharmacopoeia. The 1.0% hypromellose solution was found to be microbiologically stable for 6 months and physically stable for 12 months.
制备用于儿科的硝苯地平口服混悬液,并评估其含量均匀度以及该制剂中所用羟丙甲纤维素溶液的微生物稳定性和物理稳定性。
将六种浓度(0.5 - 3.0%)的羟丙甲纤维素胶体与作为空白对照的水,分别与硝苯地平粉末和硝苯地平碾碎片混合,配制成浓度为1 mg/mL的混悬液。采用四种不同的筛选试验来找出最均匀且剂量准确的组合。首先,将硝苯地平混悬液储存在小瓶中一个月,观察重新分散后的混悬液的视觉均匀度。其次,通过测量重新分散后的混悬液上部、中部和下部的硝苯地平浓度来研究混悬液的均匀性。接着,在振摇后立即、1分钟和2分钟测量混悬液中的硝苯地平浓度,以确保给药期间的剂量准确性。最后,将混悬液包装到一次性口服注射器中,储存一个月后测定硝苯地平浓度。根据欧洲药典规定的方法研究包装后的单剂量注射器混悬液的含量均匀度。在12个月的储存期内研究羟丙甲纤维素溶液的微生物稳定性、密度、pH值、渗透压、粘度和表面张力。
根据羟丙甲纤维素溶液的筛选试验结果,选择1.0%的羟丙甲纤维素作为由碾碎片和硝苯地平粉末制成的硝苯地平肠内混悬液的载体。由1.0%羟丙甲纤维素制成的硝苯地平混悬液最容易重新分散成均匀溶液,目视检查效果也最佳。混悬液的含量均匀度符合欧洲药典推荐的试验要求。发现1.0%的羟丙甲纤维素溶液在微生物学上稳定6个月,在物理上稳定12个月。